Aktis Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aktis Oncology, Inc. (Nasdaq: AKTS) on April 16, 2026, reporting events occurring on April 15, 2026. The filing addresses significant changes to the Company's Board of Directors, including the appointment of a new director and the resignation of two existing directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial details disclosed relate to director compensation:
- Cash Compensation: New director Glenn Gormley, MD, PhD, is entitled to $45,000 annually for Board service and $15,000 annually for serving as Co-Chairperson of the Science and Technology Committee, prorated for the service period.
- Equity Grant: Dr. Gormley was granted an option to purchase 37,866 shares of common stock at the closing price on April 15, 2026. The options vest in equal annual installments over three years.
Material Changes
The primary material change reported is the restructuring of the Board of Directors:
- Appointment: Glenn Gormley, MD, PhD, was appointed as a Class I director effective April 15, 2026. He will serve until the 2027 Annual Meeting. He was also appointed Co-Chairperson of the newly created Science and Technology Committee.
- Resignations: Helen S. Kim and Oleg Nodelman notified the Board of their resignations, effective May 20, 2026. The Company stated these resignations are not due to any disagreement regarding operations, policies, or practices.
Outlook, Risks, and Management Commentary
Management indicated that Dr. Gormley's extensive leadership and clinical development experience in the pharmaceuticals industry qualify him to serve on the Board. No specific financial guidance, outlook, or new risk factors were disclosed in this filing. The Company confirmed there are no reportable related-party transactions involving Dr. Gormley.
Key Facts for Investor Verification
- Verify the effective date of the resignations of Helen S. Kim and Oleg Nodelman (May 20, 2026) and the immediate appointment of Glenn Gormley.
- Confirm the vesting schedule of the 37,866 stock options granted to Dr. Gormley (three-year annual installments).
- Review the composition of the newly created Science and Technology Committee, co-chaired by Dr. Gormley and Ken Herrmann, MD, PhD.
- Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial metrics.